|Mr. Joseph D. Dowling||CEO, Sec. & Director||708.77k||N/A||1957|
|Mr. Joerg Grasser||Chief Financial Officer||389.23k||N/A||1975|
|Dr. Douglas Jesse MacKay ND||Sr. VP of Scientific & Regulatory Affairs||N/A||N/A||1973|
CV Sciences, Inc. operates as a life science company. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets hemp-based cannabidiol (CBD) products under the name of PlusCBD in a range of market sectors, including nutraceutical, beauty care, and specialty foods. It serves internet sales, direct-to-consumer health and wellness stores, collectives, cooperatives, master distributors, specialty retailers, and convenience stores, as well as food, drug, and mass merchandise retailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. Its products product candidates are based on proprietary formulations, processes, and technology. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
CV Sciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.